Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications
Synaffix has entered into a licensing agreement with Illumina (NASDAQ: ILMN) for its metal-free click chemistry technology. The agreement grants Illumina access to Synaffix's patented technology for use in next-generation sequencing (NGS) products.
Synaffix's technology utilizes a bicyclononyne (BCN) probe for metal-free click chemistry, primarily known for creating antibody-drug conjugates in cancer treatment. This licensing deal represents an expansion of the technology's applications into the diagnostics and sequencing field, aiming to make whole-genome sequencing more accessible.
Synaffix ha stipulato un accordo di licenza con Illumina (NASDAQ: ILMN) per la sua tecnologia di chimica click senza metallo. L'accordo consente a Illumina di accedere alla tecnologia brevettata di Synaffix per l'uso in prodotti di sequenziamento di nuova generazione (NGS).
La tecnologia di Synaffix utilizza una sonda a bicyclononyna (BCN) per la chimica click senza metallo, nota principalmente per la creazione di coniugati anticorpo-farmaco nel trattamento del cancro. Questo accordo di licenza rappresenta un'espansione delle applicazioni della tecnologia nel campo della diagnostica e del sequenziamento, mirando a rendere il sequenziamento dell'intero genoma più accessibile.
Synaffix ha entrado en un acuerdo de licencia con Illumina (NASDAQ: ILMN) para su tecnología de química click sin metal. El acuerdo otorga a Illumina acceso a la tecnología patentada de Synaffix para su uso en productos de secuenciación de nueva generación (NGS).
La tecnología de Synaffix utiliza una sonda de bicyclononina (BCN) para la química click sin metal, conocida principalmente por la creación de conjugados de anticuerpo-fármaco en el tratamiento del cáncer. Este acuerdo de licencia representa una expansión de las aplicaciones de la tecnología en el ámbito de la diagnóstico y la secuenciación, con el objetivo de hacer que el secuenciamiento del genoma completo sea más accesible.
시나픽스는 일루미나 (NASDAQ: ILMN)와 금속을 사용하지 않는 클릭 화학 기술에 대한 라이센스 계약을 체결했습니다. 이 계약은 일루미나가 차세대 시퀀싱(NGS) 제품에 사용할 수 있도록 시나픽스의 특허 기술에 접근할 수 있도록 합니다.
시나픽스의 기술은 금속이 없는 클릭 화학을 위해 bicyclononyne(BCN) 프로브를 사용하며, 주로 암 치료에서 항체-약물 접합체를 만드는 데 사용됩니다. 이 라이센스 계약은 진단 및 시퀀싱 분야로 기술 응용의 확장을 의미하며, 전체 유전체 시퀀싱을 더욱 접근 가능하게 만들고자 합니다.
Synaffix a conclu un accord de licence avec Illumina (NASDAQ: ILMN) pour sa technologie de chimie click sans métal. Cet accord accorde à Illumina un accès à la technologie brevetée de Synaffix pour une utilisation dans des produits de séquençage de nouvelle génération (NGS).
La technologie de Synaffix utilise une sonde bicyclononyn (BCN) pour la chimie click sans métal, principalement connue pour la création de conjugués anticorps-médicament dans le traitement du cancer. Cet accord de licence représente une expansion des applications de la technologie dans le domaine du diagnostic et du séquençage, visant à rendre le séquençage du génome entier plus accessible.
Synaffix hat einen Lizenzvertrag mit Illumina (NASDAQ: ILMN) für seine metallfreie Klickchemie-Technologie abgeschlossen. Die Vereinbarung gewährt Illumina Zugang zu der patentierten Technologie von Synaffix für die Verwendung in Produkten der nächsten Generation von Sequenzierung (NGS).
Die Technologie von Synaffix verwendet eine bicyclononyn (BCN) Sonde für metallfreie Klickchemie, die hauptsächlich dafür bekannt ist, Antikörper-Arzneimittel-Konjugate in der Krebsbehandlung zu erstellen. Dieser Lizenzvertrag stellt eine Erweiterung der Anwendungsgebiete der Technologie im Bereich der Diagnostik und Sequenzierung dar, mit dem Ziel, die Ganzgenom-Sequenzierung zugänglicher zu machen.
- Expansion of technology application into new market segment (DNA sequencing)
- New revenue stream through licensing agreement with major industry player
- Validation of technology's versatility beyond primary ADC applications
- None.
Insights
The licensing agreement for Synaffix's metal-free click chemistry technology represents a significant technical advancement for Illumina's NGS capabilities. The BCN (bicyclononyne) technology enables highly selective and stable chemical coupling without metal catalysts, which could potentially improve sequencing efficiency and reduce costs. This is particularly relevant for Illumina's core business of DNA sequencing.
The metal-free aspect is important as metal contamination can interfere with sensitive molecular biology processes. Integration of this technology could lead to improved sequencing accuracy and potentially help Illumina maintain its competitive edge in the NGS market. However, the financial terms and specific implementation details are not disclosed, making it difficult to quantify the immediate impact on Illumina's business performance.
While this licensing agreement demonstrates Illumina's commitment to technological innovation, the lack of financial details and specific product implementation timelines limits its immediate market impact. The deal aligns with Illumina's strategy to enhance its NGS technology portfolio but represents an incremental improvement rather than a transformative change. For investors, this development should be viewed as a long-term strategic move to maintain Illumina's market leadership position rather than a near-term value driver.
The application of click chemistry in NGS could eventually contribute to making whole-genome sequencing more cost-effective and accessible, supporting Illumina's broader market objectives. However, without concrete financial terms or commercialization timeline, the market impact remains speculative.
- Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry
- Technology to be used in Illumina's next-generation sequencing (NGS) products
Synaffix's patented metal-free click chemistry will be used in relation to certain Illumina next-generation sequencing (NGS) products.
Floris van Delft, Head of Research and Development at Synaffix, said: "At Synaffix, we are deploying a superior probe, bicyclononyne (BCN), for metal-free click chemistry for the highly selective generation of site-specific and stable antibody-drug conjugates for targeted treatment of cancer. There are also many other therapeutic applications and beyond, such as diagnostics and materials science, that can benefit from the unique chemical coupling properties of BCN. This transaction with Illumina serves as a testament to our ongoing commitment to deploy our innovative technologies in such new areas as we contribute towards making large-scale, whole-genome sequencing more accessible."
Notes to Editors
About Synaffix
Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect®, HydraSpace® and toxSYN® technologies, that together enable any company with an antibody to develop potentially best-in-class ADC products under a single license from Synaffix.
The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Synaffix holds granted patents to its technology. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen (acquired by Lepu Biopharma), Innovent Biologics, ProfoundBio (acquired by Genmab), Kyowa Kirin, Genmab, Macrogenics, Amgen, Hummingbird Biosciences, Chong Kun Dang Pharma, ABL Bio, SOTIO Biotech, BigHat Biosciences and Kivu Bioscience.
Synaffix was fully acquired by Lonza in June 2023.
About The Synaffix ADC Platform Technology
Synaffix's proprietary ADC technology platform consists of clinical-stage GlycoConnect®, HydraSpace® and toxSYN® technologies. These technologies are aimed at enabling best-in-class ADCs from any antibody, with significantly enhanced efficacy and tolerability.
GlycoConnect® conjugation technology exploits the native antibody glycan for site-specific and stable payload attachment and is tunable to any DAR format between 1 and 8. HydraSpace® compact and highly polar spacer technology further enhances therapeutic index, particularly with hydrophobic payloads. The toxSYN® linker-payload platform spans key, validated MOAs for ADC development, including potent topoisomerase 1 inhibitor (SYNtecan E™), DNA damaging agents (SYNeamicin D™ and SYNeamicin G™) and microtubule inhibitors (SYNtansine™, SYNstatin E™ and SYNstatin F™). Several unlaunched proprietary linker-payloads are being generated through the ongoing innovative efforts of the Synaffix R&D team.
For example, the newest proprietary linker-payload SYN-PNU™ represents a significantly potency-attenuated and better tolerated version of PNU-159,687 (a nemorubicin metabolite), designed with the objective to enable enhanced administered dose levels and competitive therapeutic properties versus ADCs loaded with the original PNU molecule.
The combination of these three technologies provides developers with a "one stop" and easy-to-use ADC technology platform, allowing any antibody developer to develop its own proprietary ADC and any ADC developer to expand its pipeline further and increase its competitive position.
About Lonza
Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients. Our unparalleled breadth of offerings across divisions enables our customers to commercialize their discoveries and innovations in the healthcare industry. Lonza's ambition is to improve the lives of patients by supporting and enabling our customers on the path to commercialization.
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 17,500 full-time employees, we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of
Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter
View original content:https://www.prnewswire.com/news-releases/synaffix-licenses-metal-free-click-chemistry-technology-to-illumina-for-next-generation-dna-sequencing-applications-302321573.html
SOURCE Synaffix B.V.
FAQ
What is the purpose of Illumina's licensing agreement with Synaffix?
What technology has Synaffix licensed to Illumina (ILMN)?
How will Illumina (ILMN) use Synaffix's technology?
